目的 探討防芷鼻炎片聯(lián)合氯雷他定治療變應(yīng)性鼻炎的臨床療效。方法 選取2016年8月—2017年6月于鄂州市中心醫(yī)院耳鼻喉科就診的變應(yīng)性鼻炎患者78例，隨機(jī)分為對照組（38例）和治療組（40例）。對照組患者口服枸地氯雷他定片，1片/次，1片/d。治療組患者在對照組的基礎(chǔ)上，口服防芷鼻炎片，5片/次，3次/d，飯后服用，兩組患者均治療28 d。觀察兩組患者臨床療效，比較治療前后兩組患者鼻功能評分、肺功能和血清學(xué)指標(biāo)。結(jié)果 治療后，對照組和治療組的總有效率分別為73.68%和92.50%，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。治療后，兩組鼻癢、鼻塞、噴嚏、流涕評分均明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P < 0.05）；且治療后治療組上述鼻功能評分均顯著低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P < 0.05）。兩組患者最大呼氣流速（PEF）、1秒用力呼氣容積（FEV₁）/用力肺活量（FVC）均明顯升高，PEF變異率明顯降低，同組治療前后差異有統(tǒng)計學(xué)意義（P < 0.05）；且治療后治療組的肺功能指標(biāo)顯著優(yōu)于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P < 0.05）。兩組患者免疫球蛋白IgE、IgG4、白細(xì)胞介素（IL）-4、IL-5明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P < 0.05）；且治療后治療組的血清學(xué)指標(biāo)顯著低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P < 0.05）。結(jié)論 防芷鼻炎片聯(lián)合氯雷他定治療變應(yīng)性鼻炎有較好的臨床療效，可改善患者臨床癥狀和肺功能，并減輕機(jī)體變態(tài)反應(yīng)和炎癥反應(yīng)，具有一定的臨床應(yīng)用價值。

Objective To investigate the clinical efficacy of Fangzhi Biyan Tablets combined with desloratadine in treatment of allergic rhinitis. Methods Patients (78 cases) with allergic rhinitis in Department of Otolaryngology of Ezhou Central Hospital from August 2016 to June 2017 were randomly divided into control (38 cases) and treatment (40 cases) groups. Patients in the control group were po administered with Desloratadine Citrate Disodium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Fangzhi Biyan Tablets on the basis of the control group after mail, 5 tablets/time, three times daily. Patients in two groups were treated for 28 d. After treatment, the clinical efficacy was evaluated, and the nasal function score, pulmonary function, and serum markers in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.68% and 92.50%, respectively, and there were differences between two groups (P < 0.05). After treatment, rhinocnesmus, nasal congestion, sneezing, and runny nose scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these scores in the treatment group were lower than those in the control group, with significant difference between two groups (P < 0.05). PEF and FEV₁/FVC in two groups were significantly increased, while PEF variation was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these pulmonary function indexes in the treatment group were better than those in the control group, with significant difference between two groups (P < 0.05). IgE, IgG4, IL-4, and IL-5 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And serum markers in the treatment group were lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Fangzhi Biyan Tablets combined with desloratadine has clinical curative effect in treatment of allergic rhinitis, can improve clinical symptoms and pulmonary function, and reduce allergy and inflammation, which has a certain clinical application value.